On Friday, Judge Carter granted defendant Zealthy Inc.’s motion to dismiss claims brought by Novo Nordisk under the Lanham Act and New York General Business Law. Novo Nordisk alleged that Zealthy, which markets compounded GLP-1 medications, falsely represented to consumers that those products were equivalent to Novo Nordisk’s FDA-approved medications like Ozempic and Wegovy. Compounded medications (mixed by a doctor or pharmacist for an individual patient) are not FDA-approved, even if legal to prescribe.
Novo Nordisk pointed to a cluster of statements on Zealthy’s website: that “GLP-1 medications, with active ingredient semaglutide, are FDA-approved for type 2 diabetes”; that a clinician “might prescribe FDA-approved medications like Wegovy or its active ingredient, semaglutide”; that Zealthy offers “FDA-approved weight loss medications, including semaglutide”; and similar language elsewhere describing “FDA-approved medications such as semaglutide.” Novo Nordisk argued that these statements falsely indicate that Zealthy’s compounded products are FDA-approved.
Continue Reading Judge Carter Dismisses Novo Nordisk’s False Advertising Claims, Finding Statements About Compounded GLP-1s Were Susceptible To An Accurate Reading